Sarcoma
Welcome,         Profile    Billing    Logout  
 515 Companies   302 Products   302 Products   167 Mechanisms of Action   1404 Trials   125634 News 


«12...15001501150215031504150515061507150815091510...15771578»
  • ||||||||||  Lartruvo (olaratumab) / Eli Lilly
    Review, Journal:  Olaratumab for Advanced Soft Tissue Sarcoma. (Pubmed Central) -  Jul 1, 2017   
    P3
    Of importance, this clinically meaningful increase in overall survival did not come at the expense of a significantly greater number of toxicities. A phase III confirmatory trial (ClinicalTrials.gov Identifier NCT02451943) will be completed in 2020.
  • ||||||||||  Enrollment open:  A Study of Lymphoseek (clinicaltrials.gov) -  Jun 29, 2017   
    P2,  N=27, Recruiting, 
    Trial primary completion date: Jan 2018 --> Aug 2018 Active, not recruiting --> Recruiting
  • ||||||||||  CBT-1 (tetrandrine) / CBA Pharma
    Trial initiation date, Trial primary completion date, Combination therapy, Metastases:  CBT-1 (clinicaltrials.gov) -  Jun 29, 2017   
    P1,  N=46, Not yet recruiting, 
    Recruiting --> Active, not recruiting | Trial primary completion date: May 2017 --> Nov 2017 Initiation date: Jan 2017 --> Sep 2017 | Trial primary completion date: Dec 2019 --> Sep 2020
  • ||||||||||  Halaven (eribulin mesylate) / Eisai
    Trial primary completion date:  HAL03T: A Study on Safety and Efficacy in Patients With Soft Tissue Sarcomas (clinicaltrials.gov) -  Jun 27, 2017   
    P=N/A,  N=160, Recruiting, 
    A detailed clinicopathologic correlation and supplementing the EWSR1 FISH assay with complementary methodology is mandatory for correct diagnosis. Trial primary completion date: Jun 2017 --> Nov 2018
  • ||||||||||  Trial primary completion date:  Proton or Photon RT for Retroperitoneal Sarcomas (clinicaltrials.gov) -  Jun 26, 2017   
    P1/2,  N=80, Recruiting, 
    Not yet recruiting --> Active, not recruiting | N=16 --> 20 Trial primary completion date: Jun 2017 --> Dec 2019
  • ||||||||||  robatumumab (SCH 717454) / Merck (MSD)
    Journal:  A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma. (Pubmed Central) -  Jun 25, 2017   
    P2
    This activity was observed at MK-8242 drug exposures that appear to exceed those observed in human phase 1 trials. These findings show that although the IGF-1R remains an attractive treatment target, additional research is needed to identify responders and/or means to achieve durable remissions in order to successfully exploit IGF-1R signal blockade in Ewing sarcoma (clinicaltrials.gov: NCT00617890).
  • ||||||||||  Journal:  Primary intrapelvic hemangiosarcoma in a dog. (Pubmed Central) -  Jun 25, 2017   
    At 10 weeks post-operatively, the patient died of multiple metastasis. Primary intrapelvic hemangiosarcoma is rare in dogs.
  • ||||||||||  dasatinib / Generic mfg.
    Enrollment closed, Enrollment change, Trial primary completion date:  PET Imaging of Cancer Patients Using [18F]-SKI-249380, a Radiolabeled Dasatinib-Derivative (clinicaltrials.gov) -  Jun 22, 2017   
    P1,  N=11, Active, not recruiting, 
    Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | N=20 --> 11 | Trial primary completion date: Jul 2017 --> Jul 2018
  • ||||||||||  Trial completion, Trial primary completion date, Stroma:  Treatment Response Evaluation in Gastrointestinal Stromal Tumor (GIST) Patients (clinicaltrials.gov) -  Jun 22, 2017   
    P=N/A,  N=40, Completed, 
    Recruiting --> Active, not recruiting | N=20 --> 11 | Trial primary completion date: Jul 2017 --> Jul 2018 Recruiting --> Completed | Trial primary completion date: Dec 2016 --> Jun 2017
  • ||||||||||  Cometriq (cabozantinib capsule) / Exelixis, Ipsen, Takeda, Cabometyx (cabozantinib tablet) / Takeda, Exelixis, Ipsen
    Trial primary completion date, Metastases:  Cabozantinib for Adults With Advanced Soft Tissue Sarcoma (clinicaltrials.gov) -  Jun 21, 2017   
    P2,  N=50, Recruiting, 
    Trial primary completion date: Jun 2017 --> Sep 2021 Trial primary completion date: Jun 2017 --> Jan 2018
  • ||||||||||  Opdivo (nivolumab) / BMS, Yervoy (ipilimumab) / BMS
    Enrollment change, Tumor mutational burden, PD(L)-1 Biomarker, Surgery, Metastases:  Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Sarcoma That Cannot Be Removed by Surgery (clinicaltrials.gov) -  Jun 21, 2017   
    P2,  N=110, Suspended, 
    It highlights the importance of maintaining a high level of suspicion for metastatic disease in the presence of new cutaneous findings as they may be the first evidence of advanced disease. N=84 --> 110
  • ||||||||||  CBT-1 (tetrandrine) / CBA Pharma
    Enrollment change, Trial withdrawal, Combination therapy, Metastases:  CBT-1 (clinicaltrials.gov) -  Jun 20, 2017   
    P1,  N=0, Withdrawn, 
    Trial primary completion date: Dec 2017 --> Dec 2018 N=46 --> 0 | Suspended --> Withdrawn
  • ||||||||||  RRx-001 / EpicentRx
    Biomarker, Journal:  Magnetic resonance imaging of RRx-001 pharmacodynamics in preclinical tumors. (Pubmed Central) -  Jun 19, 2017   
    The T150 min of CHP-100 tumors recovered to baseline by 24 h post-drug, suggesting a robust anti-oxidant response to the RRx-001 challenge that was presaged by a marked increase in perfusion at 1 h post-drug measured by DCE-MRI. MRI enhanced with Gd-LC7-SH provides a mechanistically rational biomarker of RRx-001 pharmacodynamics.
  • ||||||||||  Trial completion, Enrollment change, Trial primary completion date:  Charged Particle RT for Chordomas and Chondrosarcomas of the Base of Skull or Cervical Spine (clinicaltrials.gov) -  Jun 16, 2017   
    P1/2,  N=381, Completed, 
    Recruiting --> Active, not recruiting | N=26 --> 16 | Trial primary completion date: Oct 2017 --> May 2015 Active, not recruiting --> Completed | N=274 --> 381 | Trial primary completion date: Jan 2006 --> Jul 2007
  • ||||||||||  Fyarro (nanoparticle albumin-bound rapamycin) / Aadi Biosci, Opdivo (nivolumab) / BMS
    New P1 trial, PD(L)-1 Biomarker, IO biomarker, Metastases:  Nivolumab (Opdivo (clinicaltrials.gov) -  Jun 16, 2017   
    P1b,  N=40, Not yet recruiting, 
  • ||||||||||  Journal:  Highly heterogeneous genomic landscape of uterine leiomyomas by whole exome sequencing and genome-wide arrays. (Pubmed Central) -  Jun 15, 2017   
    Mutations in genes implicated in cell-to-cell interactions and remodeling of the extracellular matrix and genomic aberrations involving genes coding for the Mediator complex subunits were identified in uterine leiomyomas. Additionally, we discovered that ∼4.6% of leiomyosarcomas harbored MED12 exon 2 mutations, but the relevance of this association with molecular pathogenesis of leiomyosarcoma remains unknown.
  • ||||||||||  Journal:  Integrated Molecular Characterization of Uterine Carcinosarcoma. (Pubmed Central) -  Jun 15, 2017   
    UCSs shared proteomic features with gynecologic carcinomas and sarcomas with intermediate EMT features. Multiple somatic mutations and copy-number alterations in genes that are therapeutic targets were identified.
  • ||||||||||  Istodax (romidepsin) / Astellas, BMS
    Trial completion, Trial initiation date, Trial primary completion date, Metastases:  Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma (clinicaltrials.gov) -  Jun 14, 2017   
    P2,  N=40, Completed, 
    Multiple somatic mutations and copy-number alterations in genes that are therapeutic targets were identified. Active, not recruiting --> Completed | Initiation date: Jan 2004 --> Jan 2005 | Trial primary completion date: Jul 2013 --> Oct 2008
  • ||||||||||  DCVax-L (autologous dendritic cell vaccine leaded with autologous tumor cell lysate) / Northwest Biotherap, Opdivo (nivolumab) / BMS
    Trial initiation date, Trial primary completion date, Combination therapy, PD(L)-1 Biomarker:  Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma (clinicaltrials.gov) -  Jun 14, 2017   
    P2,  N=30, Not yet recruiting, 
    N=44 --> 30 | Completed --> Terminated; due to poor accrual Initiation date: Apr 2017 --> Aug 2017 | Trial primary completion date: Apr 2019 --> Aug 2019
  • ||||||||||  Trial completion, IO biomarker:  Predictive Study of Radiation Induced Sarcoma (clinicaltrials.gov) -  Jun 12, 2017   
    P=N/A,  N=360, Completed, 
    Initiation date: Apr 2017 --> Aug 2017 | Trial primary completion date: Apr 2019 --> Aug 2019 Enrolling by invitation --> Completed